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BRIEF REPORTS 
reflect a greater awareness of the “benefits” of aspirin 
among older physicians, a higher incidence of aches and 
pains and coronary risk factors with advancing age or the 
urge to prevent “impending” ischemic cardiac event! 
This survey was conducted before publication of the 
Physicians Health Study in the United States6 or the 
British Male Physicians trial in the United Kingdom.7 
Thus, our results probably were not influenced by publi- 
cation of these reports and subsequent media coverage of 
the “benefits” of aspirin. A major limitation of this sur- 
vey, however, is relatively small number of participants. 
Another limitation of this survey is that most repondents 
were from the Northeast United States and, therefore, 
whether these data represent attitudes of most US physi- 
cians cannot be ascertained. However, the striking in- 
crease in aspirin intake with increase in age provides a 
basis to conduct larger surveys to assess physicians’ atti- 
tudes toward novel therapy. 
Lastly, intake of a relatively small dose of aspirin 
suggests awareness among physicians that 325 mg may 
be adequate to prevent coronary events,’ possibly by dif- 
ferentially inhibiting platelet function.5 
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Pulmonary Extraction of lmmunoreactive Atrial Natriuretic Factor 
in Dogs 
Eric R. Bates, MD, Mark J. McGillem, BS, G. B. John Mancini, MD, and Roger J. Grekin, MD 
A trial natriuretic factor (ANF) is a hormone predomi- nantly secreted by the cardiac atria. It stimulates the 
kidney to produce natriuresis and diuresis, and vasodi- 
lates vascular smooth muscle. The half-life of the hor- 
mone is a few minutes, suggesting that breakdown occurs 
in many tissues.’ Significant extraction of ANF has been 
demonstrated across the capillary beds of liver, kidney 
and limb.1-3 Pulmonary extraction of the hormone has 
not been shown in dogs3 or manly2 however, even though 
rat lung homogenates destroy ANF4 and isolated rabbit 
lungs remove ANF,5 perhaps because blood samples in 
the in vivo studies were obtained from systemic arteries 
instead of pulmonary veins. If ANF is released into the 
left atria1 cavity through the thebesian veins, systemic 
arterial sampling could underestimate pulmonary extrac- 
tion of ANF. The purpose of this study was to determine 
whether ANF is extracted across the canine pulmonary 
perfusion bed. 
Surgical exposure of the heart and femoral vessels 
was accomplished in 15 mongrel dogs. Blood samples 
were withdrawn from catheters in the femoral vein, pul- 
monary artery, pulmonary artery wedge, pulmonary 
vein, left atrium, aorta and coronary sinus. Levels of 
immunoreactive ANF (IR-ANF) were measured by ra- 
dioimmunoassay after extraction with Sep-Pak car- 
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tridges (Waters Associates). Antibody was obtained 
from Peninsula Laboratories, Inc.6 
Results are listed in Table I. IR-ANF levels signifi- 
cantly increasedfrom the femoral vein to the pulmonary 
artery. Levels were significantly decreased in thepulmo- 
nary artery wedge position and the pulmonary vein, com- 
pared with the pulmonary artery. There was a significant 
step up in the left atrium, compared with thepulmonary 
vein and the pulmonary artery wedge. Left atria1 and 
aortic levels were not statistically different. Coronary 
sinus levels were 3 times higher than systemic levels. 
Although 2 human studies’s2 reported equivalent 
ANF levels in pulmonary arteries and systemic arteries, 
pulmonary wedge or pulmonary venous sampling was not 
performed and it was concluded that ANF was probably 
not extracted in the lung. Also, Wesselcouch et al3 found 
no extraction between right ventricular and left ventricu- 
lar sampling sites in the dog. Rodeheffer et al7 reported a 
decrease in ANF levels in the capillary wedge position, 
compared with equivalent levels in the pulmonary artery 
and aorta. They suggested that the hormone was extract- 
ed by the lung and secreted from the left atria1 endocardi- 
urn, rather than attenuated by the sampling technique, 
because high ANF concentrations were found in left atri- 
al tissue from a patient undergoing cardiac transplanta- 
tion. 
This study, using pulmonary venous sampling in the 
dog, demonstrates that ANF is partially extracted during 
pulmonary transit. The results confirm that samples ob- 
tained from the pulmonary wedge position accurately 
reflect pulmonary venous levels of IR-ANF. For unclear 
reasons, an amount of ANF approximately equivalent to 
dard error. 
that extracted in the lung is released into the left atria1 
cavity, presumably through the thebesian veins in the left 
atria1 endocardium, and restores systemic arterial levels 
to those found in the pulmonary artery. 
These data suggest that the lung is an important site 
for ANF extraction. The decrease in plasma ANF across 
the lung (pulmonary artery to pulmonary vein) was 17.7 
f 4.1 pmol/liter as compared with 17.3 f 4.9 pmol/liter 
across the lower extremities (aorta to femoral vein). Be- 
cause pulmonary blood flow is equal to systemic blood 
flow, these results suggest that a large proportion of ANF 
extraction occurs in the lung. It is possible that patients 
with pulmonary dysfunction have impairment of this ex- 
traction resulting in decreased clearance of the peptide. 
Such a mechanism could contribute importantly to the 
elevated ANF levels present in patients with congestive 
heart failure and pulmonary hypertension.6 Careful 
clearance studies will be required to ascertain the relative 
roles of increased secretion and decreased clearance of 
the peptide in these patients. 
The lung may also be an important target organ for 
ANF. Large numbers of ANF receptors in the lung have 
been demonstrated using autoradiography. No evidence 
has been presented to date, however, as to whether these 
are clearance receptors (c receptors) or biologically active 
receptors (b receptors). Based on the high degree of clear- 
ance of ANF by the lung, it is likely that large numbers of 
the c receptors are present. Some evidence has been pre- 
sented to suggest that ANF has biologic effects on lung 
tissue. Large doses of the peptide have been reported to 
protect against chemical-induced pulmonary edema.g 
ANF also dilates pulmonary arterieslo and has been 
shown to have bronchodilator properties. 1 l
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